Why Buy Domino’s Pizza Stock?
When you think of growth stocks, you probably imagine technology…
Buy
69
ALGS Quote, Financials, Valuation and Earnings
Last price:
$43.44
Seasonality move
:
-17.17%
Day range:
$40.30 - $44.30
52-week range:
$6.76 - $44.39
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
39.44x
P/B ratio:
3.11x
Volume:
376.3K
Avg. volume:
448.9K
1-year change:
134.7%
Market cap:
$155.8M
Revenue:
$15.5M
EPS (TTM):
-$17.11
Analysts' Opinion
-
Consensus RatingAligos Therapeutics has received a consensus rating of --. The company's average rating is a -- based on 0 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of --, Aligos Therapeutics has an estimated upside of 137.99% from its current price of $43.42.
-
Price Target DownsideAccording to analysts, the lowest downside price target is -- representing 100% downside risk from its current price of $43.42.
Fair Value
-
According to the consensus of 0 analysts, Aligos Therapeutics has 137.99% upside to fair value with a price target of -- per share.
ALGS vs. S&P 500
-
Over the past 5 trading days, Aligos Therapeutics has overperformed the S&P 500 by 0.59% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Aligos Therapeutics does not have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Aligos Therapeutics revenues have been falling on a year-over-year basis for 5 quarters in a row. In the most recent quarter Aligos Therapeutics reported revenues of $1.3M.
Earnings Growth
-
Aligos Therapeutics has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Aligos Therapeutics reported earnings per share of -$3.07.
Enterprise value:
80.9M
EV / Invested capital:
--
Price / LTM sales:
39.44x
EV / EBIT:
--
EV / Revenue:
13.48x
PEG ratio (5yr expected):
--
EV / Free cash flow:
-0.95x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
-68.4%
Net Income Margin (TTM):
-1283.19%
Return On Equity:
-118.75%
Return On Invested Capital:
-118.75%
Operating Margin:
-1586.37%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Income Statement | ||||||
| Revenue | $10.7M | $16.4M | $6M | $3.2M | $1.3M | |
| Gross Profit | -- | -- | -- | -- | -- | |
| Operating Income | -$112.8M | -$84.8M | -$94.6M | -$19.1M | -$20.1M | |
| EBITDA | -$109.1M | -$81.6M | -$91.9M | -$18.4M | -$19.5M | |
| Diluted EPS | -$66.00 | -$47.12 | -$17.11 | -$10.37 | -$3.07 | |
| Period Ending | 2020-09-30 | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $73.7M | $248.7M | $150.1M | $74.6M | $79.8M | |
| Total Assets | $92.2M | $263.1M | $164.1M | $85.9M | $88.4M | |
| Current Liabilities | $20M | $34.8M | $30.5M | $22.5M | $21M | |
| Total Liabilities | $228.9M | $46.1M | $42.1M | $31M | $38.3M | |
| Total Equity | -$136.7M | $217M | $122M | $54.8M | $50.1M | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$100.1M | -$73.1M | -$85M | -$20.3M | -$20.1M | |
| Cash From Investing | -$54.4M | $56.6M | -$38.3M | -$9K | $10.4M | |
| Cash From Financing | $595K | $513K | $88.2M | -$21K | -$4K | |
| Free Cash Flow | -$101.3M | -$73.2M | -$85.1M | -$20.3M | -$20.1M | |
ALGS
Sector
Market Cap
$155.8M
$49.2M
Price % of 52-Week High
97.82%
48.57%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.74%
1-Year Price Total Return
134.7%
-30.94%
Beta (5-Year)
--
0.754
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Buy
Level
$40.78
200-day SMA
Buy
Level
$16.97
Bollinger Bands (100)
Buy
Level
6.77 - 28.07
Chaikin Money Flow
Sell
Level
-15.1M
20-day SMA
Buy
Level
$36.11
Relative Strength Index (RSI14)
Buy
Level
74.33
ADX Line
Buy
Level
27.49
Williams %R
Sell
Level
-5.9182
50-day SMA
Buy
Level
$23.97
MACD (12, 26)
Buy
Level
5.14
25-day Aroon Oscillator
Buy
Level
80
On Balance Volume
Neutral
Level
10.9M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-4.8832)
Sell
CA Score
(Annual)
Level (-2.3677)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (9)
Sell
Ohlson Score
Level (3.7222)
--
Piotroski F Score
(Annual)
Level (--)
--
Quality Ratio Score
Level (--)
Sell
Fundamental Score
Level (3)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Aligos Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapeutics to address unmet medical needs in viral and liver diseases, including chronic hepatitis B and coronaviruses, and therapeutics for nonalcoholic steatohepatitis (NASH). The company's pipeline includes ALG-010133, ALG-000184, ALG-020572 and ALG-055009, among others.
Stock Forecast FAQ
In the current month, ALGS has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The ALGS average analyst price target in the past 3 months is --.
-
Where Will Aligos Therapeutics Stock Be In 1 Year?
According to analysts, the consensus estimate is that Aligos Therapeutics share price will rise to -- per share over the next 12 months.
-
What Do Analysts Say About Aligos Therapeutics?
Analysts are divided on their view about Aligos Therapeutics share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Aligos Therapeutics is a Sell and believe this share price will drop from its current level to --.
-
What Is Aligos Therapeutics's Price Target?
The price target for Aligos Therapeutics over the next 1-year time period is forecast to be -- according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is ALGS A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Aligos Therapeutics is a --. 0 of 0 analysts rate the stock a -- at this time.
-
How Can I Buy Shares Of ALGS?
You can purchase shares of Aligos Therapeutics via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Aligos Therapeutics shares.
-
What Is The Aligos Therapeutics Share Price Today?
Aligos Therapeutics was last trading at $43.44 per share. This represents the most recent stock quote for Aligos Therapeutics. Yesterday, Aligos Therapeutics closed at $43.42 per share.
-
How To Buy Aligos Therapeutics Stock Online?
In order to purchase Aligos Therapeutics stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
What Companies Are In The VanEck Semiconductor ETF?
There’s a lot to love about the VanEck Semiconductor ETF,…
How High Can Palantir Stock Go?
Palantir Technologies (NASDAQ:PLTR) has been one of the undisputed victors…
Stock Ideas
Buy
53
Is AAPL Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 40x
Buy
56
Is NVDA Stock a Buy?
Market Cap: $3.5T
P/E Ratio: 121x
Sell
46
Is MSFT Stock a Buy?
Market Cap: $3.1T
P/E Ratio: 36x
Alerts
Sell
39
DOGZ alert for Jan 4
Dogness (International) [DOGZ] is down 20.52% over the past day.
Buy
66
DMRC alert for Jan 4
Digimarc [DMRC] is up 16.19% over the past day.
Sell
39
MSTR alert for Jan 4
MicroStrategy [MSTR] is up 13.33% over the past day.
